Brief: Oblato Acquires All Rights To Glioblastoma Drug From OMRF

HLB Therapeutics

29/10/2018 19:03

Oct 29 (Reuters) - Oblato:
    * OBLATO ACQUIRES ALL RIGHTS TO GLIOBLASTOMA DRUG FROM OMRF
    * OBLATO - WILL INITIATE ADDITIONAL TRIALS TO STUDY EFFICACY
AND
SAFETY OF OKN-007 IN LARGER PATIENT POPULATIONS
    * OBLATO - HAS PLANS TO DEVELOP AN ORAL FORM OF OKN-007, AN
INVESTIGATIONAL DRUG FOR TREATMENT OF GLIOBLASTOMA
    * OBLATO -  WILL CONDUCT GLIOBLASTOMA CLINICAL TRIALS ON
PATIENTS
IN U.S., WILL WORK TO DEVELOP NEW DRUG WORLDWIDE

Source text for Eikon:  ID:nGNX5nmQgh 
Further company coverage:  115450.KQ 

 ((reuters.briefs@thomsonreuters.com;))